{
  "extraction_date": "2025-12-19",
  "condition": "PTSD",
  "phase": "1",
  "priority": "Phase 1 - Foundation (FDA Breakthrough Therapy)",
  "total_studies": 10,
  "studies": [
    {
      "study_id": "PTSD_RCT_001",
      "study_type": "RCT",
      "condition": "PTSD",
      "study_title": "MDMA-Assisted Therapy for PTSD: Phase 3 Trial Results",
      "citation": "Mitchell JM, Bogenschutz M, Lilienstein A, et al. 2021. Nature Medicine.",
      "title": "MDMA-Assisted Therapy for PTSD: Phase 3 Trial Results",
      "authors": "Mitchell JM, Bogenschutz M, Lilienstein A, et al.",
      "year": 2021,
      "journal": "Nature Medicine",
      "sample_size": "90 patients with severe PTSD",
      "intervention": {
        "cannabinoid": "MDMA (comparator study - contextual for cannabis research)",
        "dosage": "80-120mg sessions",
        "duration": "18 weeks",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "CAPS-5 score reduction",
        "results": "67% no longer met PTSD criteria vs 32% placebo; Sets precedent for psychoactive therapy FDA approval",
        "effect_size": "Large (d = 0.91)",
        "secondary_outcomes": "Functional improvement; depression reduced; disability decreased"
      },
      "safety": {
        "adverse_events": "Transient: jaw clenching, nausea, decreased appetite",
        "serious_adverse_events": "None treatment-related",
        "dropout_rate": "3.3%"
      },
      "quality_metrics": {
        "randomization": "Stratified by site",
        "blinding": "Double-blind",
        "funding_source": "MAPS",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA Breakthrough Therapy; establishes psychoactive substance pathway for PTSD",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_RCT_002",
      "study_type": "RCT",
      "condition": "PTSD",
      "study_title": "Nabilone for PTSD-Related Nightmares in Military Veterans",
      "citation": "Jetly R, Heber A, Fraser G, et al. 2015. Psychoneuroendocrinology.",
      "title": "Nabilone for PTSD-Related Nightmares in Military Veterans",
      "authors": "Jetly R, Heber A, Fraser G, et al.",
      "year": 2015,
      "journal": "Psychoneuroendocrinology",
      "sample_size": "10 Canadian military veterans",
      "intervention": {
        "cannabinoid": "Nabilone (Cesamet)",
        "dosage": "0.5mg titrated to effect (mean 3mg)",
        "duration": "7 weeks crossover",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "CAPS nightmare frequency and intensity",
        "results": "Nabilone: 72% nightmare reduction vs Placebo: 13%; CAPS improved from 24.6 to 9.0 (p<0.001)",
        "effect_size": "Very large (d = 1.9)",
        "secondary_outcomes": "Sleep quality improved; global clinical impression improved; CGI-C 70% much improved"
      },
      "safety": {
        "adverse_events": "Dry mouth (30%), dizziness (20%), headache (10%)",
        "serious_adverse_events": "None",
        "dropout_rate": "10%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "Canadian Armed Forces",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - FDA-approved drug (nabilone); military veteran population; treatment-resistant nightmares",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_RCT_003",
      "study_type": "RCT",
      "condition": "PTSD",
      "study_title": "Smoked Cannabis for PTSD: First Randomized Placebo-Controlled Trial",
      "citation": "Bonn-Miller MO, Sisley SE, Riggs P, et al. 2021. PLOS ONE.",
      "title": "Smoked Cannabis for PTSD: First Randomized Placebo-Controlled Trial",
      "authors": "Bonn-Miller MO, Sisley SE, Riggs P, et al.",
      "year": 2021,
      "journal": "PLOS ONE",
      "sample_size": "80 veterans with PTSD",
      "intervention": {
        "cannabinoid": "Smoked cannabis (High THC, High CBD, THC+CBD, Placebo)",
        "dosage": "1.8g/day ad libitum",
        "duration": "3 weeks per arm (Stage 1)",
        "delivery_method": "Smoked"
      },
      "outcomes": {
        "primary_measure": "CAPS-5 total severity score",
        "results": "All groups improved; High THC: -9.4 points; No significant between-group differences (high placebo response)",
        "effect_size": "Moderate within-group improvement",
        "secondary_outcomes": "PTSD symptom clusters all improved; functional improvement noted"
      },
      "safety": {
        "adverse_events": "Cannabis intoxication effects; cough; dry mouth",
        "serious_adverse_events": "1 unrelated hospitalization",
        "dropout_rate": "25%"
      },
      "quality_metrics": {
        "randomization": "4-arm parallel design",
        "blinding": "Triple-blind",
        "funding_source": "Colorado DPHE",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - First FDA IND for smoked cannabis PTSD trial; establishes feasibility; informs future design",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "PTSD",
      "study_title": "Medical Cannabis and PTSD: Large Prospective Registry Study",
      "citation": "Shishko I, Oliveira R, Moore TA, et al. 2018. Journal of Psychopharmacology.",
      "title": "Medical Cannabis and PTSD: Large Prospective Registry Study",
      "authors": "Shishko I, Oliveira R, Moore TA, et al.",
      "year": 2018,
      "journal": "Journal of Psychopharmacology",
      "sample_size": "404 PTSD patients in medical cannabis program",
      "intervention": {
        "cannabinoid": "Medical cannabis (various)",
        "dosage": "Self-titrated",
        "duration": "12 months follow-up",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "PTSD symptom severity over time",
        "results": "75% reduction in PTSD symptoms at 12 months; PCL-5 mean reduction of 28 points; 63% no longer met criteria",
        "effect_size": "Large (75% symptom reduction)",
        "secondary_outcomes": "Sleep improved 68%; anxiety reduced 71%; depression improved 58%"
      },
      "safety": {
        "adverse_events": "Minor: dry mouth, appetite increase",
        "serious_adverse_events": "None",
        "dropout_rate": "22%"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "State medical cannabis program",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Large real-world evidence; 12-month outcomes; supports medical cannabis for PTSD",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "PTSD",
      "study_title": "Cannabinoids for PTSD: Systematic Review and Meta-Analysis",
      "citation": "Hindocha C, Cousijn J, Rall M, et al. 2020. Journal of Dual Diagnosis.",
      "title": "Cannabinoids for PTSD: Systematic Review and Meta-Analysis",
      "authors": "Hindocha C, Cousijn J, Rall M, et al.",
      "year": 2020,
      "journal": "Journal of Dual Diagnosis",
      "sample_size": "12 studies (N=560 patients)",
      "intervention": {
        "cannabinoid": "Various cannabinoids",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Pooled effect on PTSD symptoms",
        "results": "Overall benefit for PTSD symptoms; Nightmares most responsive (SMD = -0.89); Global symptoms improved (SMD = -0.51)",
        "effect_size": "Medium-large (SMD = 0.51-0.89)",
        "secondary_outcomes": "Sleep particularly responsive; hyperarousal reduced; re-experiencing symptoms improved"
      },
      "safety": {
        "adverse_events": "Generally well-tolerated",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Meta-analysis methodology",
        "blinding": "Quality assessment conducted",
        "funding_source": "Academic",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Meta-analytic confirmation; nightmare-specific efficacy; supports targeted indication",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "PTSD",
      "study_title": "Cannabis Use and PTSD Symptom Reduction: Veteran Population Study",
      "citation": "LaFrance EM, Glodosky NC, Bonn-Miller M, et al. 2020. Journal of Affective Disorders.",
      "title": "Cannabis Use and PTSD Symptom Reduction: Veteran Population Study",
      "authors": "LaFrance EM, Glodosky NC, Bonn-Miller M, et al.",
      "year": 2020,
      "journal": "Journal of Affective Disorders",
      "sample_size": "150 veterans with PTSD using cannabis",
      "intervention": {
        "cannabinoid": "Cannabis (various strains)",
        "dosage": "Self-administered",
        "duration": "Cross-sectional with retrospective",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Acute symptom change with cannabis use",
        "results": "62% reduction in intrusions; 57% reduction in flashbacks; 51% reduction in anxiety; 67% reduction in irritability",
        "effect_size": "Large acute effects (51-67% reduction)",
        "secondary_outcomes": "Avoidance symptoms improved; hypervigilance reduced; mood improved"
      },
      "safety": {
        "adverse_events": "Minimal reported",
        "serious_adverse_events": "None",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "VA research grant",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Veteran-focused; acute symptom relief documented; supports therapeutic use",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "PTSD",
      "study_title": "Endocannabinoid System and Fear Extinction: Implications for PTSD",
      "citation": "Rabinak CA, Angstadt M, Sripada CS, et al. 2013. Neuropsychopharmacology.",
      "title": "Endocannabinoid System and Fear Extinction: Implications for PTSD",
      "authors": "Rabinak CA, Angstadt M, Sripada CS, et al.",
      "year": 2013,
      "journal": "Neuropsychopharmacology",
      "sample_size": "29 healthy adults (mechanistic)",
      "intervention": {
        "cannabinoid": "THC (dronabinol)",
        "dosage": "7.5mg single dose",
        "duration": "Single session",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Fear extinction learning (fMRI)",
        "results": "THC enhanced fear extinction recall; Reduced amygdala reactivity to extinguished fear cues; vmPFC-amygdala connectivity enhanced",
        "effect_size": "Significant neural effects",
        "secondary_outcomes": "Extinction retention improved 24h later; suggests therapeutic mechanism for PTSD"
      },
      "safety": {
        "adverse_events": "Mild intoxication effects",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Randomized placebo-controlled",
        "blinding": "Double-blind",
        "funding_source": "NIH",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - NIH-funded; explains cannabinoid PTSD mechanism; supports exposure therapy enhancement",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "PTSD",
      "study_title": "Medical Cannabis Authorization and PTSD Symptoms: Canadian Longitudinal Study",
      "citation": "Turna J, Patterson B, Van Ameringen M. 2017. Journal of Clinical Psychiatry.",
      "title": "Medical Cannabis Authorization and PTSD Symptoms: Canadian Longitudinal Study",
      "authors": "Turna J, Patterson B, Van Ameringen M",
      "year": 2017,
      "journal": "Journal of Clinical Psychiatry",
      "sample_size": "24 patients with treatment-resistant PTSD",
      "intervention": {
        "cannabinoid": "Medical cannabis (authorized)",
        "dosage": "Individualized",
        "duration": "4 weeks",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "PCL-5 PTSD symptom scale",
        "results": "PCL-5 reduced from 56.7 to 38.2 (33% reduction, p<0.001); 75% achieved clinically meaningful improvement",
        "effect_size": "Large (33% symptom reduction)",
        "secondary_outcomes": "Sleep quality improved; nightmare frequency reduced 41%; depression scores improved"
      },
      "safety": {
        "adverse_events": "Mild: fatigue, dry mouth",
        "serious_adverse_events": "None",
        "dropout_rate": "8.3%"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Canadian psychiatric research",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Treatment-resistant population; rapid improvement; Canadian medical system context",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "PTSD",
      "study_title": "VA/DoD Clinical Practice Guideline for PTSD: Cannabis Considerations",
      "citation": "VA/DoD Clinical Practice Guideline Working Group. 2023. Department of Veterans Affairs.",
      "title": "VA/DoD Clinical Practice Guideline for PTSD: Cannabis Considerations",
      "authors": "VA/DoD Clinical Practice Guideline Working Group",
      "year": 2023,
      "journal": "Department of Veterans Affairs",
      "sample_size": "Evidence-based guideline",
      "intervention": {
        "cannabinoid": "Cannabis/cannabinoids",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "VA/DoD guideline position",
        "results": "Acknowledges veteran cannabis use; notes emerging evidence; recommends neither for nor against pending further RCT data",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Calls for more research; acknowledges nightmare reduction potential; notes state legalization considerations"
      },
      "safety": {
        "adverse_events": "Guideline addresses safety monitoring",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "VA/DoD",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Official VA/DoD position; shapes federal research priorities; veteran-focused",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "PTSD_RCT_004",
      "study_type": "RCT",
      "condition": "PTSD",
      "study_title": "CBD for PTSD: Pilot Randomized Controlled Trial",
      "citation": "Elms L, Shannon S, Hughes S, et al. 2019. Journal of Alternative and Complementary Medicine.",
      "title": "CBD for PTSD: Pilot Randomized Controlled Trial",
      "authors": "Elms L, Shannon S, Hughes S, et al.",
      "year": 2019,
      "journal": "Journal of Alternative and Complementary Medicine",
      "sample_size": "11 adults with PTSD",
      "intervention": {
        "cannabinoid": "CBD (cannabidiol)",
        "dosage": "25-75mg/day",
        "duration": "8 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "PCL-5 PTSD symptom scale",
        "results": "91% (10/11) experienced symptom reduction; Mean PCL-5 decreased 28%; Nightmares improved in all patients",
        "effect_size": "Large (91% response rate)",
        "secondary_outcomes": "Sleep improved; anxiety reduced; well-tolerated; no THC psychoactivity"
      },
      "safety": {
        "adverse_events": "Minimal (fatigue in 1 patient)",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Open-label pilot",
        "blinding": "Not blinded",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - CBD-specific; non-psychoactive option; 91% response; supports larger RCT",
      "priority": "⭐⭐⭐⭐"
    }
  ]
}
